EMD Serono, a biopharmaceutical business based in North America under Merck KGaA of Darmstadt, Germany, recently announced that it has published the 12th edition of its Specialty Digest publication.
“EMD Serono has a longstanding commitment to customers and patients to further the understanding of trends in the management of specialty pharmaceuticals and ultimately, improve patient outcomes,” Scott Filosi, senior vice president of market access and customer solutions for EMD Serono, said. “It is our hope that this year’s Digest findings will help spur conversations around ways to ensure continued patient access to optimal care.”
The publication was recently featured at the Asembia Specialty Pharmacy Summit located in Las Vegas, Nevada. The Digest is an important resource for the health industry, as it offers market data for managing health plans, particularly for pharmaceuticals. It also points out common trends that are happening within health plans.
“The findings in the area of oncology shed light on new trends such as the adoption of clinical pathways as well as concerns around restricting product use and the cost of infusion site visits for payers,” Artemetrx President Kevin Host, who oversaw the development of this year’s Digest, said. “Understanding these managed care challenges as they relate to oncology is an important step in better meeting the needs of patients.”
The new publication includes data taken from 58 commercial health plans in the U.S. These data represent over 140 million people.
